Clinical trial
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small…
NCT00193518 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193518 |
|---|---|
| Title | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Official title | A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | CTI BioPharma Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma |
| Intervention type | Drug |
| Interventions | Arsenic Trioxide |
| Enrollment | 41 |
| Start date | Apr 1, 2004 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | May 3, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: